GLP-1 receptor agonist for diabetes and weight management with established clinical data.
Patients seeking proven, cost-effective diabetes control with established cardiovascular benefits, or those preferring a more established medication with greater insurance coverage.
Dual GIP/GLP-1 receptor agonist delivering superior weight loss and diabetes control through dual-pathway mechanism.
Patients prioritizing maximum weight loss, optimal diabetes control, or those who haven't achieved goals with single-pathway GLP-1 agents, and those with adequate insurance coverage.
Ozempic (semaglutide) is a GLP-1 receptor agonist approved for type 2 diabetes and weight loss, while Mounjaro (tirzepatide) is a newer GIP/GLP-1 receptor agonist showing superior weight loss results. Mounjaro targets two pathways compared to Ozempic's single pathway, making it potentially more effective for weight management.
Mounjaro demonstrates superior weight loss and diabetes control due to its dual-mechanism approach, making it the better choice for maximum results. However, Ozempic remains established with more clinical history, better availability, and lower cost, making it ideal for those seeking proven efficacy or budget-conscious patients. The choice depends on individual goals, insurance coverage, and medical history.
Choose Ozempic if
Patients seeking proven, cost-effective diabetes control with established cardiovascular benefits, or those preferring a more established medication with greater insurance coverage.
Get notified when prices change, new specs ship, or our verdict updates.
Triggers: price change new spec verdict update
No spam. Stop anytime.
| Metric | Ozempic | Mounjaro | Diff |
|---|---|---|---|
| Monthly Cost (without insurance)(USD) | ~$900 | — | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — | — |
| FDA Approval Year(year) | 2017 | — | — |
| Number of Dose Strengths Available(strengths) | 4 | — | — |
| Typical Weight Loss at Maximum Dose |
Wegovy vs Ozempic
health
Wegovy vs Ozempic
products
Ozempic vs Wegovy
health
Tylenol vs Advil
health
Almond Milk vs Oat Milk
health
Vegan vs Vegetarian
health
Keto vs Paleo
health
Running vs Walking
health
Yoga vs Pilates
health
Flu Shot vs COVID Vaccine
health
Organic Food vs Non-Organic Food
health
Therapy vs Medication
health
Choose Mounjaro if
Patients prioritizing maximum weight loss, optimal diabetes control, or those who haven't achieved goals with single-pathway GLP-1 agents, and those with adequate insurance coverage.
| 5-7% |
| — |
| — |
| FDA Approval Year(year) | 2017 (diabetes) | — | — |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | — | — |
| Injection Frequency(times per week) | 1 | — | — |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200 | — | — |
| Time to Maintenance Dose(weeks) | 12 | — | — |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0 | — | — |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | 20-22% | -21% |
| A1C Reduction(percentage points) | 1.5-2.0% | 1.8-2.3% | -15% |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | 2023 | — |
| Injection Schedule(per week) | Once weekly | Once weekly | — |
| Average Retail Price(USD/month) | $900-1,300 | $1,000-1,500 | -12% |
| Number of Dose Strengths Available(options) | 3 | 7 | -57% |
| Time on Market(years) | 9 years | 3 years | +200% |
All figures sourced from publicly available data. Last updated May 2026.
Ozempic
GLP-1 receptor agonist
Mounjaro
GIP/GLP-1 receptor agonist (dual agonist)🏆
Ozempic
15-18% body weight
Mounjaro
20-22% body weight🏆
Ozempic
Approved (Wegovy brand, 2021)🏆
Mounjaro
Approved (Zepbound brand, 2023)
Ozempic
Once weekly
Mounjaro
Once weekly
Ozempic
0.5, 1.0, 2.4 mg
Mounjaro
2.5, 5, 7.5, 10, 12.5, 15 mg🏆
Ozempic
Widely available since 2017🏆
Mounjaro
More recent, expanding supply
Ozempic
$900-1,300 USD🏆
Mounjaro
$1,000-1,500 USD
Ozempic
1.5-2.0% reduction
Mounjaro
1.8-2.3% reduction🏆
Both have similar side effect profiles including nausea, vomiting, and diarrhea, especially at higher doses. Mounjaro users report slightly more GI side effects initially due to its dual mechanism, but these typically resolve within 2-4 weeks. Ozempic has more long-term safety data due to its earlier release. Serious side effects like pancreatitis are rare with both medications.
Dive deeper with these curated resources
As an affiliate, we may earn a commission from qualifying purchases at no extra cost to you. Learn more
| Attribute | Mounjaro | |
|---|---|---|
| Average Weight Loss(% body weight) | 8-12% | — |
| Typical Weight Loss at Maximum Dose(% of body weight) | 5-7% | — |
| Average Weight Loss (Clinical Trial)(% body weight) | 15-18% | 20-22% |
| A1C Reduction(percentage points) | 1.5-2.0% | 1.8-2.3% |
| Monthly Cost (without insurance)(USD) | ~$900 | — |
| Average Monthly Cost (Uninsured)(USD) | $900-1,200 | — |
| Average Retail Price(USD/month) | $900-1,300 | $1,000-1,500 |
| Active Ingredient | Semaglutide | — |
| Maximum Weekly Dose(mg) | 2.0 mg | — |
| FDA Approval Year(year) | 2017 | — |
| FDA Approval Year(year) | 2017 (diabetes) | — |
| FDA Approval Year (Weight Loss Indication)(year) | 2021 | 2023 |
| Primary Indication | Type 2 Diabetes | — |
| Cardiovascular Benefits | Proven in diabetic patients | — |
| Typical Insurance Coverage | Widely covered for diabetes | — |
| Number of Dose Strengths Available(strengths) | 4 | — |
| Active Ingredient | Semaglutide (GLP-1 receptor agonist) | — |
| Nausea/Vomiting Incidence(% of patients) | 25-40% | — |
| Injection Frequency(times per week) | 1 | — |
| Injection Schedule(per week) | Once weekly | Once weekly |
| Time to Maintenance Dose(weeks) | 12 | — |
| HbA1c Reduction in Diabetics(percentage points) | 1.5-2.0 | — |
| Active Ingredient Mechanism | GLP-1 receptor agonist (single pathway) | GIP and GLP-1 receptor agonist (dual pathway) |
| Number of Dose Strengths Available(options) | 3 | 7 |
| Time on Market(years) | 9 years | 3 years |
Side-by-side comparison of numeric attributes